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Abstract
Background and purpose: Vascular dementia (VAD) is a complex diagnosis at
times difficult to distinguish from Alzheimer’s disease (AD). MRI scans often
show white matter hyperintensities (WMH) in both conditions. WMH increase
with age, and both VAD and AD are associated with aging, thus presenting an
attribution conundrum. In this study, we sought to show whether the amount
of WMH in deep white matter (dWMH), versus periventricular white matter
(PVH), would aid in the distinction between VAD and AD, independent of
age. Methods: Blinded semiquantitative ratings of WMH validated by objective
quantitation of WMH volume from standardized MRI image acquisitions. PVH
and dWMH were rated separately and independently by two different examiners using the Scheltens scale. Receiver operator characteristic (ROC) curves were
generated using logistic regression to assess classification of VAD (13 patients)
versus AD (129 patients). Clinical diagnoses were made in a specialty memory
disorders clinic. Results: Using PVH rating alone, overall classification (area
under the ROC curve, AUC) was 75%, due only to the difference in age
between VAD and AD patients in our study and not PVH. In contrast, dWMH
rating produced 86% classification accuracy with no independent contribution
from age. A global Longstreth rating that combines dWMH and PVH gave an
88% AUC. Conclusions: Increased dWMH indicate a higher likelihood of VAD
versus AD. Assessment of dWMH on MRI scans using Scheltens and Longstreth
scales may aid the clinician in distinguishing the two conditions.

Introduction
White matter hyperintensities (WMH) on magnetic resonance imaging (MRI) have a heterogeneous underlying
neuropathology, variable genetics, and complex relationship with clinical symptoms and associated copathologies
(Drayer 1988; Kertesz et al. 1990; Debette and Markus
2010). Patients with Alzheimer’s disease (AD) and vascular dementia (VaD), although they may both demonstrate
WMH on MRI scans, may have differing relationships
between WMH and clinical symptoms leading to diagno-

sis. WMH on MRI may serve as a marker for more widespread white
matter
microstructural
alterations
measurable using nonstandard MRI techniques (Maillard
et al. 2014; Maniega et al. 2015; Tuladhar et al. 2015a;
Wang et al. 2015a).
Variable patterns of WMH distribution have been
associated with specific risk factors, such as stroke, alcohol abuse, and tobacco use (Rostrup et al. 2012). Deep
WMH (dWMH) refers to hyperintensities in the centrum
semiovale and other deep white matter extending up to
the subcortical U-fibers, in contrast to hyperintensities
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immediately bordering the lateral ventricles, termed
periventricular WMH (PVH; Fig. 1). Increased dWMH
versus PVH have been found in normal communitydwelling persons with lower scores on tests of executive
function (Soriano-Raya et al. 2012), in patients with significant hypertension (Firbank et al. 2007) and in
patients with depression (Krishnan et al. 2006). Patients
with diabetes demonstrate association of slowed processing speed with dWMH, whereas PVH are associated with
reduced attention and executive function (Tiehuis et al.
2008). Thus, there is evidence for a potentially useful distinction between deep and periventricular WMH.
In this study we examined the relationship between
dWMH and PVH in patients clinically diagnosed with either
AD or VaD. We performed independent semiquantitative
ratings of WMH, and quantified WMH volume to validate
these ratings. We found that dWMH, in contrast to PVH,
predicted the diagnosis of VaD, indicating that dWMH are a
substrate of more profound impairment than PVH.

Methods
Participant characteristics
We collected the MRI scans from 210 subjects who
underwent evaluation in an outpatient specialist memory
disorders clinic at the University of Kentucky Alzheimers
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Disease Center (ADC) in a 40-month time window as
described previously in detail (Schmitt et al. 2012).
Patients were referred from the community for the evaluation because of a memory complaint or suspected
dementia, typically suspected AD. Presence of a caregiver
was required to provide a reliable history. Each patient
underwent a full neurologic and medical examination,
and had laboratory testing including hemogram, electrolytes, liver and renal function tests, thyroid function
studies, serum B12 and folate levels, and other laboratories as deemed appropriate. After evaluation, including
consideration of the MRI scan formal report, patients
were given a diagnosis and prescribed treatment. Patients
provided consent (together with a caregiver or relative)
under University of Kentucky Medical Institutional
Review Board approved procedures.
Diagnosis of possible and probable AD used NIAADRC criteria, and possible or probable vascular dementia (VaD) was based on the extended Hachinski Ischemic
Scale (Lau et al. 1988) and DSM-IV (American Psychiatric Association, 2000) criteria. Current terminology now
includes VaD under the rubric “Vascular cognitive
impairment or dementia” (VCID), but we retained the
VaD designation because subjects were diagnosed as such
under DSM-IV. Frontotemporal dementia, dementia with
Lewy bodies, corticobasal degeneration, multisystem atrophy, and normal pressure hydrocephalus (NPH) were
diagnosed according to published literature standards.
Mild cognitive impairment used “age associated memory
impairment” criteria current at the time of study (Crook
and Larrabee 1991), prior to the Peterson criteria era.
Two patients without a recorded diagnosis had largevessel infarcts by MRI (one old left anterior cerebral
artery, one acute right parietal infarct). One patient with
an old right frontal infarct was diagnosed possible AD,
but excluded because of this confounding pathology. An
additional patient diagnosed as possible VAD harbored a
large right ventricular cyst and was thus excluded due to
the presence of this potentially cofounding pathology.
Exclusions are summarized in Table 1. After exclusions,
142 subjects remained in the group for study, 129 with
AD diagnosis, and 13 with VaD.

Scan protocol

Figure 1. Illustration of dWMH versus PVH. PVH are indicated by
paired facing arrowheads on the right; dWMH are indicated by arrow.
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A standardized MRI imaging protocol was performed on
clinical Siemens 1.5 T magnetic resonance imaging scanners according to a dementia-specific sequence series.
This series included a sagittal scout, axial T1-weighted,
T2-weighted, and proton density (PD) images, and two
T1-weighted coronal series, the first in a standard orientation and a second series oblique oriented parallel to the
main axis of the hippocampus. For segmentation and
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Table 1. Number of Subjects excluded for diagnoses other than
Vascular dementia or Alzheimer’s disease.

Diagnosis

Excluded subjects
(technical excludes)

Dementia NOS
MCI
Metabolic
VaD*
MSA-P
AD*
CBD
DLB
FTD
NPH
Not Demented
No Diagnosis
Total

10 (1)
8 (2)
2 (0)
3 (3)
1 (0)
10 (10)
2 (0)
2 (0)
5 (1)
1 (0)
3 (1)
19 (2)
68 (20)

The number of subjects excluded because of technical problems with
the scans (excessive motion, missing images or variation from standard protocol) is given in parentheses. Patients with AD or VaD diagnosis were only excluded for poor technical quality of the scans.
CBD, corticobasal ganglionic dementia; DLB, dementia with Lewy
bodies; FTD, frontotemporal dementia; MCI, mild cognitive impairment; MSA-P, multisystem atrophy, parkinsonian type; NOS, not
otherwise specified; NPH, normal pressure hydrocephalus; VaD, vascular dementia; AD, Alzheimer’s disease.
*Two/Three VaD excluded due to poor scan quality, 1/3 excluded
because of a large right ventricular cyst treated as a confound.

analysis of WMH, the following sequences were used:
Axial images, 0.898 9 0.898 9 5 mm, TR 2600, TE
27 ms (PD) and TE 81 ms (T2-weighted), and T1weighted with TR 610 ms, and TE 14 ms. All series consisted of 19 slices with a 1.5 mm interslice gap.

Image processing and rating & validation
PD and T2 images were affine registered and resliced into
the native images space of the T1 image in SPM8 (http://
www.fil.ion.ucl.ac.uk/spm/). The T1 image was skullstripped using the FSL version 5.07 Brain Extraction Tool
(BET v2.1) with robust center estimation (http://fsl.fm
rib.ox.ac.uk/fsl). The binary extraction mask isolated the
brain portion of the PD and T2 images by multiplication.
These images were then field-corrected using the N3 algorithm (Fig. 2A). Residual skull signal was removed during
the segmentation step.
Continuing in SPM8, the New Segment protocol was
followed with the skull-stripped, N3-corrected T1 and T2
images entered into a multimodal segmentation with
component gray matter (GM), white matter (WM), and
cerebrospinal fluid (CSF). The PD image did not improve
segmentation. A template created from a separate group
of 146 similar-aged normal subjects was applied during
segmentation.
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Component GM, WM, and CSF images are scaled to
intensity values between zero and one. Total component
volumes were estimated by thresholding each component
image at 0.333, and summing the voxel volumes. Importantly in this method, WM was modeled in New Segment
as two separate tissues, each incorporating two gaussians.
The sum of these tissues gave more reliable total WM
segmentation than when a single tissue alone represented
WM (Fig. 2B).
The segmented WM image was converted to a binary
mask with a threshold of 0.333, and dilated once in
2.5 days to create a WM mask (MIPAV version 7.1.1
morphology; http://mipav.cit.nih.gov/). The dilation step
expanded the outline of the binary mask to capture
WMH at the WM – CSF boundary that may have been
misclassified in the segmentation due to partial volume
effects.
Next the skull-stripped, registered, N3-corrected PD
image was multiplied by the WM mask to remove CSF
and GM voxels (Fig. 2C). The histogram of this WMextracted PD image was fit with a gaussian profile to estimate a mean and standard deviation (MIPAV version
7.1.1). A P-value of 0.01 was chosen as the threshold to
define WMH (2.33 9 SD) relative to the WM voxel mean
in each individual image (Fig. 2D). The thresholded PD
image was smoothed with a resolution normalized
(z = 1) gaussian kernel filter to remove noise pixels.
Hand-editing was often necessary to remove artifacts in
the remaining image, particularly at the base of the brain
at the level of the large blood vessels. The total volume of
hyperintensities exceeding the threshold was recorded for
each subject as total WMH volume.
In order to compare images at similar contrast, ratings
on the Scheltens, Fazekas, and Longstreth scales were
made on PD images in a darkened room with the display
window center set at the histogram mean, and window
width set at ten times the standard deviation. The Scheletens and Fazekas scales require separate scoring for
dWMH and PVH. PVH represent bands and caps that
follow the contour of the lateral ventricles with variable
thickness and degrees of irregularity. Deep WMH extend
from the immediate periventricular region of PVH
through the centrum semiovale and other regions of deep
white matter to the subcortical U-fibers. Scheltens PVH
are scored on a 0–6 scale and dWMH on a 24 point scale,
guided by explicit definitions for size and number of
hyperintenstities in each region. We used this scale as our
primary visual rating because of its specificity and scale
range. Fazekas ratings capture global aspects of dWMH
and PVH, each on a 0–3 point scale. The Longstreth scale
rates density, confluence, and extent of WMH on a 0–9
range without explicitly distinguishing PVH from
dWMH.
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Figure 2. Processing steps for WMH volume measurement. (A) Top
row: (left to right, a–c), original T1-, T2-, and PD-weighted images;
Bottom row (d–f): corresponding skull-stripped, N3-corrected images.
(B) Segmented images. Top row (left to right, g–i): gray- and whitematter (WM) segmentations; two tissues were modeled for WM
because of the signal differences between normal-appearing WM and
WM hyperintensities. Bottom row: CSF(j), total WM (sum of h+i), and
sum of GM(g), WM(k), and CSF(j) images(l). (C) Masking. Top row
(left to right): succession of WM masks beginning with WM
segmented image, followed by thresholded binary WM image, and
dilated binary WM image. Rightmost image is skull-stripped PD
image. Bottom row: PD image masked by dilated WM binary, masked
image thresholded at 2.33 S.D., gaussian-filtered image, final edited
WMH image for quantitation. (D) Histogram demonstrating gaussian
fit and threshold value (black arrowhead). Note shoulder in the
histogram on the right representing WMH plus tail of WM gaussian
pixel distribution.

Rating scales and validation
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(D)

Two independent observers followed the same protocol
described to gain an estimate of repeatability and reliability of WMH measures in 34 subjects. Interobserver measurement of WMH showed a linear correlation coefficient
adjusted r2 of 0.95, with a regression slope of 0.98, and
offset (intercept) of 190 voxels. Nonparametric rank correlations between observers for WMH volume and WM
rating scales are shown in Table 2A. Reliability was greatest for the WMH volume protocol, followed in order by
Longstreth rating, Scheltens deep WMH rating, and
Scheltens PVH rating (Scheltens et al. 1993) (all correlation P-values < 0.0001). In our hands the Fazekas ratings
were less reliable than for Scheltens. Observer 2 Fazekas
ratings were less reliable relative to total WMH volume
than observer 1’s. Validity of the WMH volume measurement protocol was assessed by correlating WMH volume
with both WMH rating scales (Table 2B), demonstrating
satisfactory reliability on all scales.
These comparisons show strong correlations, but do
not imply a direct numerical correspondence between
observers on any of the WMH measures. Rather, the
comparisons show that the measures increase together
strongly and coherently. They also show that increasing
WMH volume corresponds to what clinicians see as
increased WMH on T2-weighted images, for example,
using the Longstreth scale.

Statistical methods
Comparisons of means used two sample t-tests; comparison of proportions used chi-square tests; comparison of
Hachinski scores used a Wilcoxon rank sum test (JMP
version 9). For analysis of WMH, logistic regression
models were calculated incorporating log-transformed ratings as the independent variables, and age at MRI scan,
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Table 2. (A) Spearman rank correlations between WMH volume and WMH rating scales from two independent observers in 34 subjects, as a validation of the reliability of the WMH measurement protocol. (B) Rank correlations between WMH volume and WMH rating scales for observer 1,
who performed measurements on all 142 subjects.

Observer 2
(A)
WMH Volume
Longstreth
Scheltens PVH
Scheltens Deep WMH
Fazekas PVH
Fazekas Deep WMH

Observer 1
(B)
WMH Volume

WMH volume

Longstreth

Scheltens PVH

Scheltens deep WMH

Fazekas
PVH

Fazekas
deep WMH

0.93
<0.0001
0.94
<0.0001
0.59
0.0002
0.44
0.009
0.45
0.03
0.45
0.03

0.96
<0.0001
0.82
<0.0001
0.72
<0.0001
0.68
<0.0001
0.61
0.002
0.54
0.01

0.49
0.003
0.69
<0.0001
0.65
<0.0001
0.44
0.009
0.38
0.08
0.34
0.12

0.36
0.03
0.64
<0.0001
0.45
0.007
0.77
<0.0001
0.38
0.08
0.48
0.02

0.54
0.01
0.59
<0.0001
0.28
0.19
0.50
0.02
0.36
0.10
0.27
0.23

0.58
0.004
0.69
<0.0001
0.58
0.005
0.64
0.001
0.59
0.004
0.67
0.0006

Longstreth

Scheltens PVH

Scheltens Deep WMH

Fazekas
PVH

Fazekas
Deep WMH

0.83
<0.0001

0.72
<0.0001

0.60
<0.0001

0.55
<0.0001

0.71
<0.0001

WMH, white matter hyperintensities; PVH, periventricular white matter.
P-value for correlation given under coefficient.

gender, education, whole-brain volume in cubic centimeters, MMSE, and Hachinski score as adjustment variables,
with diagnosis (VaD vs. AD) as the outcome. Effect testing used the likelihood ratio; a P-value of 0.05 or less was
considered significant.
To normalize distributions, all measures of WMH were
scaled by adding 0.5 (to avoid zero) and then by taking the
natural logarithm of the result (log normal transform).
Log-normalized scales were treated as continuous variables.
Measures of WMH were added to separate models as follows: (1) Two Scheltens scales for Caps and Bands (range
0–6), and for white matter hyperintensities (range 0–24
(Scheltens et al. 1993)), (2) Longstreth rating of WMH
(Longstreth et al. 1996) (range 0–9), and (3) WMH
volume. Receiver operator characteristic (ROC) curves and
tables were computed from each of the three models.

Results
Demographic and testing variables are shown in Table 3.
Only mean age at MRI scan differed between VaD and
AD patients; the VaD patients were approximately 5 years
older. Nine percent of the patients had VaD, the others
were diagnosed with AD.
Logistic regression incorporating two Scheltens scales
demonstrates that only the deep WMH rating was significantly related to the diagnosis of VaD (Table 4). Adjustment variables reaching significance were education in the
Longstreth regression (LR chi-square 4.5, P = 0.03), and,
as expected from its relationship with the diagnosis of
VaD, the Hachinski score (P-values between 0.002 and
0.0001). Periventricular hyperintensity rating was not significant. Both the Longstreth rating and WMH volume

Table 3. Demographic and testing data. VaD patients were older than the AD patients on average, and had higher Hachinski scores.
Diagnosis (n)

Age, years

Male/Female (n)

Education, years

MMSE (0–30)

Hachinski (Mod 0–13)

AD (129)
VaD (13)
Compared

75.1  7.6
80.5  6.4
t = 2.5 P = 0.01

42/89
5/8
X2 = 0.22
P = 0.7

12.5  4.0
13.4  4.1
t = 0.81
P = 0.42

19.4  4.9
19.3  5.4
t = 0.00
P = 0.95

0 [0–1]
3 [1–5.5]
X2 = 13.7
P = 0.0002

AD, Alzheimer’s disease; VaD, vascular dementia; MMSE, mini-mental status examination score (range 0–30).
X2 = ChiSquare; Hachinski vascular dementia score, median [IQR], Wilcoxon Test.
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Table 4. Results of logistic regression model for WMH using standard
ratings of PVH and dWMH (first and second rows; Scheltens, Fazekas),
and total WMH (third and fourth rows; Longstreth and WMH
volume). Including an interaction term for age and WMH did not alter
the result. We found a similar effect with both the Scheltens and
Fazekas scales, despite the wider score range of the Scheltens scale.
AD versus VaD

PVH

dWMH

Total WMH

Scheltens

LR
P
LR
P
–

–

Longstreth

LR
P
LR
P
–

WMH Volume

–

Fazekas

1.9
= 0.17
0.23
= 0.63

–

11.5
= 0.0007
11.6
= 0.0006

–
LR
P
LR
P

15.1
= 0.0001
12.2
= 0.0005

LR, Likelihood ratio chi-square; WMH, white matter hyperintensities;
PVH, periventricular white matter; dWMH, deep white matter;
AD, Alzheimer’s disease; VaD, vascular dementia.

were significantly related to the diagnosis of VaD, but
neither of these measures distinguished deep from
periventricular hyperintensity.
The ROC curves for Scheltens ratings (area under the
curve (AUC) 86%) and total white matter volume (AUC
85%) were essentially identical (Fig. 3). The ROC curve
for Fazekas ratings was similar (AUC 87%, not shown).
The Longstreth rating gave a slightly better overall performance in predicting VaD versus AD (Fig. 3B, solid line;
AUC 88%). At optimum, the Longstreth scale had an
85% sensitivity and 68% specificity for VaD. In contrast,
the model without any WMH measures had an AUC of
71%, with optimum of 54% sensitivity and 48% specificity, close to chance. This weak prediction was related
only to the increased age of our VaD patients previously
noted in Table 3.

Discussion
The most important finding of our study was that deep
white matter hyperintensities (dWMH) better distinguish
VaD from AD than periventricular hyperintensities
(PVH). Two different semiquantitative rating scales that
separately rate dWMH and PVH on MRI brain images,
Scheletens and Fazekas, gave similar results. We interpret
these finding to mean that clinicians, in evaluating standard clinical FLAIR and T2-weighted MRI studies of the
brain, can sharpen assessment of VaD by increasing focus
on dWMH in addition to other vascular findings such as
lacunar infarcts, microbleeds, and focal encephalomalacia
(Noh et al. 2014). The simplest explanation is that larger
amounts of dWMH are associated with increasing disruption of brain networks concerned with executive function,
gait stability, and urinary control. Recent studies have
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shown that specific tracts crossing regions of WMH may
show corresponding expected functional consequences
(Jacobs et al. 2012; Birdsill et al. 2014; Duering et al.
2014; Tuladhar et al. 2015b).
We also found that increased scores on a global rating
scale, Longstreth (Longstreth et al. 1996), was associated
with VaD. There was a very strong relationship between
objectively measured total white matter hyperintensity
volume (PVH plus dWMH) and Longstreth rating, supporting the validity of that semiquantitative observerbased scale. The Longstreth scale was developed as a tool
to assess effects of vascular disease on the brain, and rates
both PVH and dWMH together, under the assumption
that PVH and deep WMH extents increase together.
While this is generally true, there appears to be value in
separating PVH and dWMH in the evaluation of VaD.
We emphasize that the scans were performed on routinely available clinical scanners using a standard clinical
imaging protocol. Although we performed quantitation of
WMH under a rigorous image processing protocol in this
study, this was used mainly for validation. In addition,
the protocol can be implemented using publicly available
image processing programs without using special proprietary scripts (available in detail from the first author).
Moreover, it is not necessary to use these programs, as
we showed strong correlation between WMH rating
scores and WMH volume. The relationship was logarithmic, and showed that increased WMH volume is strongly
predictive of what a clinician means by increased WMH
when evaluating a scan, consistent with other studies
(Gouw et al. 2006, 2008a). Thus, for aiding diagnosis of
VaD, semiquantitative ratings are sufficient.
The common form of white matter hyperintensities
may comprise two types: a type associated with vascular
injury to small vessels, due to long-standing hypertension
for example, and a second type of uncertain etiology
related to aging (Fazekas et al. 1998; Smith et al. 2000a,
b). Distinguishing between the two may be difficult
because vessel damage from cerebrovascular disease
increases with duration of disease (e.g., age), and the
aging-associated type may involve, at least partially, a vascular component distinct from atheroscerosis or hypertensive injury (arteriolosclerosis).
Periventricular white matter abnormalities particularly
are age-related and likely due to alterations in cerebrospinal fluid dynamics at the ependymal lining of the
ventricles, in some instances associated with ventricular
enlargement. Deep white matter hyperintensities are
pathologically heterogeneous, in some cases consisting of
focally widened spaces lined by atrophic myelin centered
on fibrohyalinized vessels, and in others larger areas of
gliosis, myelin rarefaction, and fiber loss consistent with
ischemia (Gouw et al. 2011; Schmidt et al. 2011). The
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(A)

(B)

Figure 3. Receiver operator characteristic
(ROC) curves for models described in
Statistical Methods section. These curves
indicate quality of the classification VAD
versus AD; increased performance curves
approach the left and upper borders of the
graph. (A) Comparison between Scheltens
dWMH and PVH ratings demonstrating
improved classification of VAD using
dWMH (dashed line) compared to PVH
(dotted line), (B) Comparison of overall
WMH rating methods. Scheltens (dashed
line) and WMH volume (dotted line) show
similar classification performance, slightly
improved with Longstreth (solid line).

first kind of dWMH appears as scattered punctate foci on
MRI have no proven clinical significance. Deep white
matter dilated perivascular spaces, recently associated with
altered cerebrospinal fluid drainage dynamics (Weller
et al. 2015), should not be confused with these punctate
foci.
The second dWMH kind is vascular in nature (Young
et al. 2008), most likely to increase over time, and associ-

ª 2016 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.

ated with clinical evidence of executive dysfunction, gait
difficulties, and urinary abnormalities (Maillard et al.
2012; Chutinet and Rost 2014; Allan et al. 2015). The
midlife CAIDE dementia risk score, that includes hypertension, obesity, cholesterol, and physical activity factors,
predicts WMH volume 20 years later (Vuorinen et al.
2015), although in cross-sectional studies these factors are
better predictors of large artery disease than WMH
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(Wardlaw et al. 2014). Diabetes is recognized as another
cause of microvascular pathology (Nelson et al. 2009).
Increased WMH are associated with decreased gray matter
and CSF volumes (Zi et al. 2014), but the contribution of
cardiovascular risk factors to this relationship has been
questioned recently (Wang et al. 2014; Arvanitakis et al.
2015).
Heterogeneity in genetic influence on WMH has also
recently been demonstrated by the finding that heritability
was significantly higher in hypertensive (0.41) versus nonhypertensive (0.13) individuals in a 2243 patient GWAS
study (Adib-Samii et al. 2015). Single-nucleotide polymorphisms (SNPs) predicting WMH were different
between hypertensive and nonhypertensive patients
(Adib-Samii et al. 2015; Haffner et al. 2015). So far the
only genetic locus clearly identified as associated with
WMH is 17q25; the salient gene or genes within this
locus remains unknown (Fornage et al. 2011). The presence of apolipoprotein epsilon-4 allele (ApoE4), a known
strong genetic risk factor for AD, strengthened the relationship between vascular risk factors and increased
WMH. Although controversial (Brickman et al. 2014,
2015), symptomatic noncarriers have shown greater
WMH than ApoE4 carriers, perhaps because WMH then
become a stronger determinant of cognitive alterations
(Morgen et al. 2015).
Other modifiers of WMH may include comorbid
pathologies such as AD, where increased WMH has been
found in some studies (Gouw et al. 2008b; Chui and
Ramirez-Gomez 2015). In AD, frontal cortical thinning
has been associated with WMH and executive dysfunction
(Ye et al. 2015). Alterations in myelin integrity found in
AD may be secondary to axonal fiber loss or injury
(Radanovic et al. 2013). Presence of these AD alterations
may confer vulnerability of the axon-myelin unit to specific non-AD injury types (Erten-Lyons et al. 2013; Kim
et al. 2015), reflected genetically as different arrays of
SNPs predicting WMH and suggesting synergisms (Chao
et al. 2013; Yoon et al. 2013; Kester et al. 2014). However, in a recent longitudinal study of cognition in baseline normal subjects, amyloid burden-defined AD
pathology and MRI-defined vascular pathology appeared
to represent independent processes, with only additive,
not multiplicative, effects on rate of cognitive decline, a
conclusion supported by others (Lo and Jagust 2012;
Barnes et al. 2013; Haight et al. 2013; Vemuri et al. 2015).
We interpret our results to mean that increased
dWMH are more likely to be associated with a diagnosis
of VaD than AD. A strong caveat to this interpretation is
that the images were known to the clinicians making the
diagnosis, and therefore the finding could represent a
“self-fulfilling prophecy” since WMH are evident on the
scans. There are two reasons we think this is not the case,
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although we cannot entirely exclude it. First, clinicians
used radiologist reports of scans rather than performing
semiquantitative ratings or WMH volume measurements
on the scans themselves. As scans on AD patients are
often also reported as showing “periventricular white
matter ischemic lesions”, matters of extent or deep versus
periventricular pattern are not detailed in these reports.
Second, Hachinski scores were increased in the VaD
group. Clinical features are embedded in the Hachinski
scale, not scan findings, including subcortical pattern of
impairment, presence of hypertension or stroke, and
characterization of progression. AD patients had a
Hachinski score median of zero, clearly different from the
VaD patients (median 3). The interquartile range overlapped between the AD and VaD group at one, suggesting
the groups were quite different on clinical findings underlying the diagnosis.
One explanation for the unique contribution of
dWMH to VaD diagnosis is the increased potential for
the disruption of multiple functionally important networks supporting cognition (Medaglia et al. 2015).
Decoupling of functional and structural connectivity by
WMH has been demonstrated in recent studies (Reijmer
et al. 2015; Wang et al. 2015b). Local functional regions
tend to be densely connected, with these dense sets of
nodes linked by sparse long-range connections (Park and
Friston 2013). An association has been shown between
clinical depression and dWMH in the superior longitudinal fasciculus within the frontal lobe, suggesting that
dWMH could disrupt critical long-range integrative pathways (Sheline et al. 2008). While global WMH burden
has been related to diminished network connectivity and
impaired cognition (Pinter et al. 2015; Tuladhar et al.
2016), much further work is needed to relate regional
WMH within specific tracts and the functional and cognitive consequences thereof.
Caution in the interpretation of our results is in order.
Our patients were seen in a memory disorders clinic
where the frequency of AD was high, and it is in this setting that our findings are most relevant. Patients with
large-vessel stroke were rare in this clinic and for that reason we could not address the issue of VaD subtypes
involving such strokes. We did not have pathologic confirmation that small vessel disease was the predominant
pathology explaining dementia, thus our interpretation
remains on clinical grounds. Our model for WMH
adjusted for differences in age, gender, education, whole
brain volume, MMSE, and Hachinski score. Nonetheless,
it should be kept in mind that the number of patients
with VaD was relatively small.
In summary, we suggest clinicians focus on dWMH as
a clue to vascular contributions to cognitive impairment
and to rate their scans as part of clinical data collection,

ª 2016 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.

C. D Smith et al.

whether explicitly as dWMH versus PVH (Fazekas, Scheltens) or with emphasis on dWMH as part of a global
WMH rating such as Longstreth. The way we now think
of dWMH is that they reflect not a surrogate measure of
vascular risk, but rather the impact of vascular risk factors
on deep white matter. In some cases, we observe extensive
dWMH in the absence of canonical vascular risk,
nonetheless indicating impact, but from as yet unknown,
perhaps genetic, influences.
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